Confirmatory factor analysis of the Patient Assessment of Constipation-Symptoms (PAC-SYM) among patients with chronic constipation by Neri, L. et al.
Confirmatory factor analysis of the Patient Assessment
of Constipation-Symptoms (PAC-SYM) among patients
with chronic constipation
Luca Neri • Paul Maurice Conway •
Guido Basilisco • Laxative Inadequate Relief Survey
(LIRS) Group
Accepted: 3 December 2014 / Published online: 19 December 2014
 Springer International Publishing Switzerland 2014
Abstract
Background and aim PAC-SYM is widely adopted to
asses constipation severity. However, it has been validated
in a small sample, few items have been included based on
expert opinion and not on empirical grounds, and its factor
structure has never been replicated. We aimed at evaluating
the psychometric properties of PAC-SYM in patients with
chronic constipation.
Methods We enrolled 2,203 outpatients with chronic
constipation in two waves. We used wave I sample to test
the psychometric properties of the PAC-SYM and wave II
sample to cross-validate its factor structure, to assess cri-
terion validity, responsiveness to clinical change, and its
minimal clinically important difference.
Results Only a minority of patients reported any rectal
tearing (38 %). Deletion of such item leads to a 11-item
version (M:PAC-SYM). The remaining items in the rectal
domain were moderately correlated with the stool domain.
Exploratory factor analysis and confirmatory factor analysis
revealed a bifactor structure with two subscales (stool and
abdominal symptoms) and a general severity factor. The
M:PAC-SYM demonstrated excellent reliability, moderate
correlation with SF-12 and treatment satisfaction
(r = 0.28–0.45), discrimination across Rome III criteria for
functional constipation and abdominal pain, and responsive-
ness to clinical change (b = -0.49; x2 = 0.25). M:PAC-
SYM minimal clinically important difference was 0.24.
Conclusion Our analysis shows that the rectal domain
may not represent a relevant cluster of symptoms for
patients with chronic constipation. We developed a modi-
fied version of the PAC-SYM which might better represent
symptom severity of most patients seeking care in gastro-
enterology referral centers.
Keywords Constipation severity  Quality of life 
Chronic non-organic constipation  Chronic constipation
Introduction
Assessment of patient-reported outcomes is a key issue in
functional gastrointestinal disorders since the diagnosis of
these conditions, the assessment of disease severity and
treatment outcomes is based on symptoms. Multi-item
symptoms questionnaires are often used to assess the
effectiveness of medications and to predict the improve-
ment of quality of life in randomized controlled trials.
However, these questionnaires are prone to a number of
bias which may result in fallacious conclusions with regard
to treatment efficacy and tolerability [1].
The Patient Assessment of Constipation-Symptoms
(PAC-SYM) is a 12-item self-report questionnaire
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subdivided in three symptom subscales (i.e., abdominal,
stool, and rectal). The initial psychometric evaluation
provided evidence that the PAC-SYM is a reliable and
valid instrument assessing the severity of constipation in
adult patients, in which it can detect clinically meaningful
changes over time and distinguish between responders and
non-responders to treatment [2].
The PAC-SYM has recently been used in the integrated
analysis of three double-blind placebo-controlled trials
with prucalopride in women who reported inadequate relief
from laxatives at trial entry [3]. In line with the results in
the original studies [4–6], the effect of prucalopride was
smaller for rectal than for abdominal and stool symptoms
subscales and the proportion of patients with a PAC-SYM
severity score [2 at baseline was 50 and 71 % for
abdominal and stool symptoms, but only 15 % for rectal
symptoms; in the analysis of individual item scores, the
smallest effect of prucalopride was observed for two items
of the rectal symptom subscale, namely ‘‘rectal burning’’
and ‘‘rectal bleeding/tearing.’’ Items ‘‘rectal bleeding/tear-
ing’’ and ‘‘rectal burning’’ have been included in the ori-
ginal questionnaire [2] based on clinical judgment, but not
on empirical findings. In fact, such symptoms were fairly
infrequent in the validation sample [2], and thus captured
non-relevant complains for the majority of patients.
Although some evidence of invariance of PAC-SYM in
different samples has been obtained in older adults in long-
term care facilities [2] and in patients with low back pain
and opioid-induced constipation [7], no attempts to repli-
cate the factor structure, responsiveness to clinical change
and construct validity of the PAC-SYM questionnaire have
been carried out in patients with chronic constipation.
Replication addresses how well factors generalize across
samples drawn from the same population [8]. Hence, we
aimed at evaluating the psychometric properties of the
PAC-SYM questionnaire with its subscales and character-
izing its relationship with key outcomes such as quality of
life and treatment satisfaction.
Methods
The present study is a part of the Laxative Inadequate
Relief Survey (LIRS), aiming at evaluating quality of life,
treatments satisfaction, activity impairment, and health
care utilization among patients with chronic constipation in
39 Italian referral centers for functional gastrointestinal
disorders. The study consisted of two waves: In LIRS I, a
cross-sectional survey, 878 consecutive outpatients were
enrolled from September through December 2011. In LIRS
II, a repeated measure survey, 1,325 outpatients from the
same centers were enrolled, of whom 45 were assessed
twice or more from March 2012 to May 2013.
Patients’ eligibility was ascertained by a gastroenterol-
ogist during an outpatient clinical examination in both
waves. Patients reporting at least two of the Rome III
criteria for functional constipation [9] were included after
exclusion of any organic cause of gastrointestinal symp-
toms. Abdominal pain or discomfort lasting at least 3 days/
month in the past 3 months, a symptoms associated with
irritable bowel syndrome with constipation (IBS-C), was
not used as criterion of exclusion given the wide overlap
between IBS-C and functional constipation [10]. A gas-
troenterologist recorded three possible features of abdom-
inal pain in a data collection form: (1) relieved by
defecation; (2) changed after the meal; and (3) represented
the most bothersome complain for the patient. The same
gastroenterologist recorded patients’ age, sex, BMI,
smoking habit, daily intake of water, time since constipa-
tion onset, pregnancies, difficult deliveries, previous
abdominal and extra-abdominal surgical intervention,
concomitant diseases, and treatment regimens during a
regular outpatient visit.
We matched clinical data with a self-administered
questionnaire completed by each patient.
Measures
The questionnaires included the PAC-SYM [2], the Italian
version of the RAND SF-12 [11] and the Treatment Sat-
isfaction Questionnaire for Medication (TSQM-v2) [12].
The PAC-SYM questionnaire consists of 12 items in three
domains: abdominal symptoms [abdominal, ABD: 4 items:
(1) discomfort in your abdomen, (2) pain in your abdomen,
(3) bloating in your abdomen, and (4) stomach cramps],
rectal symptoms [rectal, REC: 3 items: (5) painful bowel
movements, (6) rectal burning during or after a bowel
movement, (7) rectal bleeding or tearing during or after
bowel movement] and stool symptoms [stool, STO: 5
items: (8) incomplete bowel movement like you did not
finish, (9) bowel movement that were too hard, (10) bowel
movement that were too small, (11) straining or squeezing
to try to pass bowel movements, (12) feeling like you had
to pass a bowel movement but you could not]. Ratings
occur along a five-point Likert scale (form 0 = absence of
symptoms to 4 = very severe). The TSQM-v2 assesses
patients’ satisfaction with treatment effectiveness, side
effects, and convenience. Summary scores are calculated
using a 0–100 scale, with higher scores corresponding to
higher treatment satisfaction [12].
Additionally, the LIRS II questionnaire included a sec-
tion inquiring about therapy switching in the past month.
Patients were asked to rate clinical change after therapy
switch with a bipolar global rating of change scale (GRC,
15 point, from -7 = extremely deteriorated to ?7=extre-
mely improved) [13]. It has been suggested that the
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minimal clinically important difference (MCID) for the
GRC scale is two point [13]. For this reason, we classified
patients’ ratings as follows: -7 to -5 = very deteriorated;
-4 to -2: deteriorated; -1 to 1 = unchanged; ?2 to
?4 = improved; and ?5 to ?7 = very improved.
Analysis
All analyses have been conducted with SAS 9.2. We used
the LIRS I sample to test basic psychometric properties and
construct validity of the PAC-SYM questionnaire (item
ceiling and floor effect, convergent and divergent validity,
factor structure, and internal consistency) and the LIRS II
sample to test criterion validity (association with other
relevant self-reported outcomes, i.e., treatment satisfaction,
quality of life, and global rating of change scores) and
assess the minimal clinically important difference for the
PAC-SYM scores. Using principal component analysis, the
original validation study revealed the existence of three
subscales of symptoms making up the PAC-SYM
(abdominal, rectal and stool) [2]. Hence, we adopted a
multi-trait approach to test items convergent and discrim-
inant validity across the proposed three subscales. We
generated an inter-item correlation matrix: All correlations
B0.35 among items belonging to the same hypothesized
scale suggest lack of convergent validity (i.e., items might
not represent the same construct). Internal consistency was
evaluated by computing Cronbach’s a. We also tabulated
the item-total correlations, indicating the association
between individual items and the total scores (all sub-
scales). Correlations between sub-scale scores and any item
which do not belong to that scale C0.40 suggest lack of
divergent validity (i.e., items might not discriminate across
the hypothesized constructs). We then carried out a con-
firmatory factor analysis (CFA) and compared the fit of five
different models thought to explain patients’ responses to
PAC-SYM items.
Model 1 (Appendix 1 of Electronic Supplementary
Material, panel 1): Since PAC-SYM total score is con-
sidered an overall measure of constipation severity and it is
often used as outcome measure in RCTs or predictor
measure in observational studies [3–6], Model 1 hypothe-
sized a single-factor structure, i.e., all items belonging to a
general severity scale with no abdominal, rectal, or stool
subscales.
Model 2 and 3 (Appendix 1, panels 2–3): To account for
the three-dimensional structure empirically observed in the
validation study by Frank et al. [2], we tested both an
uncorrelated and an inter-correlated three-factor structure
(i.e., abdominal, rectal, and stool factors).
Model 4 (Appendix 1, panel 4): We tested the hypothesis
that a higher-order PAC-SYM factor can account for the
three lower-order factors, i.e., a general severity explaining
three lower-order factors to which all items belong.
Model 5: We tested a bi-factor structure [14] which
assumes that the three sub-scale scores add unique infor-
mation beyond (i.e., after adjustment for) the general severity
factor. This model would reconcile both the empirical factor
structure and current use in clinical research.
Factor loadings were required to be[0.3 and statistically
significant (P\ 0.05) for each item to be considered as an
adequate indicator of the respective hypothesized construct.
We adopted the root mean square error of approximation
(RMSEA), the goodness of fit index (GFI), and the normed v2
index for evaluatingmodel fit: RMSEA\ 0.10; GFI C 0.90
and normed v2\ 5 are considered to indicate acceptable fit
[15]. To compare the fit of the hypothesizedmodels, we used
the Akaike information criteria (AIC), the Swartz Bayesian
criteria (SBC), and the v2 test (the latter for nested models).
Lower values of theAIC andSBC indicate that a givenmodel
has a better fit compared with a competing one, taking also
criteria of parsimony into account.
We calculated Spearman’s correlations to evaluate the
association between PAC-SYM score and other relevant
outcome measures. We evaluated whether PAC-SYM score
and its subscales discriminate across clinically different
subgroups (defined by abdominal pain and items of the
Rome III criteria) by reporting absolute difference and effect
size (Cohen’s d or x2 where appropriate). For large samples,
the use of conventional p value thresholds is of little
meaning, while clinical relevance is to be preferred as
decisional criterion. We assessed PAC-SYM responsiveness
to change by evaluating its ability to discriminate across
patients reporting improvement, stability, or deterioration on
the GRC scale. The minimal clinical important difference
(MCID) for PAC-SYM score was calculated by using a
random intercept model to evaluate longitudinal variation in
PAC-SYM score and GRC scale in 45 patients who were
repeatedly assessed in the LIRS II survey. PAC-SYM score
was included in the model as time-varying covariate. The
MCID corresponded to the PAC-SYM coefficient estimate
associated with a two-point increase in the GRC scale. This
anchor-based method was compared with a distribution-
based method to derive MCID: According to distribution-
based criteria, the MCID for a patient-reported outcome
ranges between 0.2 and 0.5 effect size [16–22].
Results
Study sample
Characteristics of patients enrolled in the LIRS I and LIRS
II studies are described in Table 1. LIRS I and LIRS II
samples were substantially similar relative to patients’
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characteristics. The average age was 50 years (SD 16.7)
and 80 % of patients were women. In both samples, the
most prevalent complain was straining followed by reports
of lumpy or hard stools and sensation of incomplete
evacuation in more than one quarter of defecations. Half of
the patients had more than two comorbid medical condi-
tions. Most patients received multiple therapies for con-
stipation in the 3 months prior to the interview.
Ceiling and floor effect
PAC-SYM items have been completed in full by 97.5 % of
patients in the LIRS I sample. Ceiling (i.e., scores at the top
of the scale) and floor (i.e., scores at the bottom of the
scale) effects for the total score were negligible. On the
contrary, we observed a sizeable floor effect in the items
concerning the rectal domain (items 5–7) and in item 4
(Table 2).
Convergent validity
Inter-item correlations (r3–4 = 0.33, r5–7 = 0.31,
r8–9 = 0.34) reveal that items 3 and 4, 5 and 7, 8 and 9 might
not represent the same constructs (Table 3).
Divergent validity
Both the correlations of items 5 (painful bowel movement)
and 6 (rectal burning during or after a bowel movement)
with the STO score were r = 0.40, thus suggesting that
answers to these questions thought to belong to the REC
scale might be partially explained by defecation-/stool-
related problems.
Internal consistency
The standardized Cronbach’s a of each subscale exceeded
a[ 0.70 (ABD 0.80; REC 0.72; STO 0.80). Standardized a
slightly increased after the deletion of item 4 (a = 0.81)
and item 7 (a = 0.74) from the scales to which they
Table 1 Characteristics of patients with chronic constipation enrol-
led in the LIRS I and LIRS II studies and in the whole sample







Mean age (years) 50.1 (16.7) 50.3 (16.6) 49.9 (16.9)
Women 1,808 (82.1) 706 (80.4) 1,102 (83.2)
Employed 1,090 (49.5) 370 (42.1) 720 (54.3)
Rome III criteria
Lumpy/hard stools 1,638 (74.4) 659 (75.1) 979 (73.9)
Incomplete
evacuation
1,604 (72.8) 650 (74.0) 954 (72.1)
Obstruction 346 (40.4) 346 (40.4) 507 (38.3)
Manual maneuvers 539 (24.5) 220 (25.1) 319 (24.1)
\3 Defecations/
week
1,501 (68.2) 565 (64.4) 936 (70.7)
Strain 1,812 (82.3) 723 (82.4) 1,089 (82.3)
Mean time since
disease onset (years)
11.9 (13.7) 17.3 (15.0) 7.0 (10.2)
Abdominal pain 369 (16.8) 149 (17.0) 220 (16.6)
Therapy
Diet/other 266 (12.2) 125 (14.6) 141 (10.7)
Bulking/osmotic 157 (7.2) 43 (5.0) 114 (8.6)
Stimulant/herbal 113 (5.2) 52 (6.1) 61 (4.6)
Enema 58 (2.7) 23 (2.7) 35 (2.6)
Multi-drug 1,352 (62.0) 563 (65.7) 789 (59.6)
None 107 (4.9) 51 (5.9) 56 (4.2)
Prucalopridea – N/Aa 151 (11.4)
Water[1 L/day 1,325 (60.3) 537 (61.7) 788 (59.5)
Current smoker (Y) 806 (36.6) 325 (38.1) 477 (36.0)
Comorbidity index 2.4 (2.0) 2.5 (2.1) 2.3 (1.9)
BMI 23.6 (4.1) 23.8 (4.0) 23.5 (4.3)
Data are mean (SD) or N (%)
a Prucalopride was not available in Italy during LIRS I







1. Discomfort in your abdomen 5.54 15.64 1.77 (1.10)
2. Pain in your abdomen 3.94 25.06 1.47 (1.13)
3. Bloating in your abdomen 14.25 7.60 2.23 (1.14)
4. Stomach cramps 2.17 50.30 0.91 (1.09)
5. Painful bowel movement 4.58 37.76 1.24 (1.21)
6. Rectal burning during or after a
bowel movement
5.00 37.26 1.23 (1.21)
7. Rectal tearing or bleeding after a
bowel movement
2.86 61.70 0.71 (1.08)
8. Incomplete bowel movement, like
you didn’t ‘‘finish’’
11.91 10.97 2.09 (1.16)
9. Bowel movement that were too
hard
13.70 11.10 2.20 (1.18)
10. Bowel movement that were too
small
9.28 19.29 1.84 (1.24)
11. Straining or squeezing to try to
pass bowel movements
20.43 7.08 2.44 (1.16)
12. Feeling like you had to pass a
bowel movement you couldn’t
11.11 24.35 1.76 (1.33)
Ceiling and floor effects represent the proportion of patients reporting
the highest possible and lowest possible score for each item. Mean
values for the single items are also reported
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belong. Standardized a for the total PAC-SYM score was
0.83.
Confirmatory/exploratory factor analysis
Competing models are illustrated in Appendix 1 and
described in the ‘‘Methods’’ section.
Model 1 (single-factor model, Appendix 1, panel 1): Fit
indexes (RMSEA = 0.17; normed v2 = 25.6; GFI = 0.75;
AIC = 1,277 and SBC = 1,022) indicated that this model
did not fit the data appropriately.
Model 2 (uncorrelated three-factor model, Appendix 1, panel
2): Model 2 significantly improvedmodel fit (RMSEA = 0.12;
normed v2 = 12.3; GFI = 0.87; AIC = 558 and SBC = 302;
v2 test for comparison of nested models: p\0.01) and all item
loadings were[0.40. However, general model fit was still
unsatisfactory.
Model 3 (correlated three-factor model, Appendix 1,
panel 3): Model 3 allowed that inter-correlations among
the three factors (i.e., ABD, REC, STO) would be freely
estimated. This new specification slightly improved fit
compared with Model 2 (RMSEA = 0.09; normed
v2 = 7.7; GFI = 0.92; AIC = 289 and SBC = 48; v2 test
for comparison of nested models: p\ 0.01). Parameter
estimates indicated moderate inter-correlations among
factors (range r = 0.36–0.57), which may indicate that a
second-order factor exists.
Model 4 (one second-order factor and three first-order
factors, Appendix 1, panel 4):Model 4 hypothesized that one
second-order underlying factor (i.e., constipation severity)
can account for the three first-order factors (i.e., ABD, REC,
STO). This model slightly improved fit compared with
Model 3 (RMSEA = 0.09; normed v2 = 6.8; GFI = 0.93;
AIC = 246 and SBC = 11; v2 test for comparison of nested
models: p\ 0.01). However, modification indexes for
Model 4 showed that direct paths from the second-order
factor to the PAC-SYM items would improve model fit,
suggesting a structure consistent with a bi-factor model.
Model 5 (bi-factor model): we tested a bi-factormodelwith
individual items loading on both a general factor (i.e., con-
stipation severity) and the three first-order factors (i.e., ABD,
REC, STO). Model 5a improved fit compared with Model 4
(RMSEA = 0.06; normed v2 = 3.6; GFI = 0.97; AIC = 69
and SBC = -96; v2 test for comparison of nested models:
p\ 0.01). Modification indexes also suggested that error
terms between items 8, 9, and 12 should be allowed to covary,
which is clinically plausible. A newmodel (Model 5b) further
improved model fit (RMSEA = 0.04; normed v2 = 2.4;
GFI = 0.98; AIC = 15 and SBC = -141; v2 test for com-
parison of nested models: p\ 0.01).
Model 6 (revised bi-factor model Fig. 1): Even though
the fit of Model 5b to the data appeared satisfactory, our
results showed that divergent validity was questionable for
items grouped in the REC subscale. Items 5 and 6 had high
correlations with the STO subscale, while item 7 had a
strong floor effect which may impact scale responsiveness
to clinical change. Hence, we removed item 7 and ran an
exploratory factor analysis which revealed two factors: the
ABD (items 1–4), which was identical to the original one
and the M-STO (items 5, 6, 8–12) which incorporated
items 5 and 6. Such results suggests that the rectal scale
reproducibility is questionable. We then tested a bi-factor
model with two first-order factors (Model 6a). Even though
this model fitted the data adequately, it did not provide a
significant improvement compared with Model 5a
(RMSEA = 0.08; normed v2 = 6.1; GFI = 0.96;
Table 3 Multi-trait analysis of item convergent and divergent validity
Dimension Item ABD REC STO Total scores
1 2 3 4 5 6 7 8 9 10 11 12 ABD REC STO
ABD 1 – 0.84 0.20 0.31
2 0.69 – 0.83 0.26 0.30
3 0.60 0.50 – 0.77 0.23 0.32
4 0.40 0.47 0.33 – 0.69 0.32 0.28
REC 5 0.27 0.38 0.25 0.34 – 0.38 0.80 0.40
6 0.19 0.20 0.21 0.29 0.58 – 0.27 0.86 0.40
7 0.01 0.05 0.08 0.13 0.31 0.49 – 0.08 0.72 0.22
STO 8 0.32 0.28 0.32 0.25 0.32 0.35 0.19 – 0.36 0.36 0.70
9 0.14 0.14 0.16 0.15 0.28 0.28 0.16 0.34 – 0.18 0.30 0.75
10 0.20 0.18 0.23 0.19 0.25 0.23 0.18 0.37 0.57 – 0.25 0.28 0.74
11 0.22 0.23 0.23 0.18 0.33 0.34 0.16 0.47 0.59 0.44 – 0.26 0.35 0.78
12 0.27 0.29 0.28 0.28 0.32 0.30 0.15 0.47 0.36 0.37 0.48 – 0.35 0.32 0.73
Table displays inter-item and item-total Pearson’s correlation coefficients. Items 3, 4, 5, 7, 8, 9 might not represent their hypothesized construct
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AIC = 123 and SBC = -14). Modification indexes sug-
gested that error terms of: Items 1 (abdominal discomfort)
and 3 (bloating); 4 (stomach cramps) and 5 (painful bowel
movement); and 9 (bowel movement too hard), 10 (bowel
movement too small) and 11 (squeeze/strain to pass bowel
movement) should be allowed to correlate, possibly indi-
cating a co-occurrence of such symptoms. Since these co-
variations are clinically plausible, we tested a new model
(Fig. 1) allowing the estimation of such error covariance
parameters. The new specification (Model 6b) strongly
improved model fit (RMSEA = 0.04; normed v2 = 2.4;
GFI = 0.98; AIC = 17 and SBC = -107; v2 test for
comparison of nested models: p\ 0.01).
Cross-validation. To assess whether the new bi-factor
model with two first-layer factors is stable across samples
of the same population, we tested the same Model 6b in the
LIRS II sample obtaining similar fit statistics
(RMSEA = 0.04; normed v2 = 3.6; GFI = 0.99; AIC =
43 and SBC = -95). The internal consistency of the
M-PAC-SYM score (a = 0.88) and its subscales (ABD;
a = 0.83; M-STO; a = 0.87) was excellent.
Discriminant validity
Discrimination of the modified PAC-SYM total (M-PAC-
SYM) and its subscales scores (ABD and M-STO) across
clinically relevant groups defined by Rome III criteria was
tested in the LIRS II sample and presented in Table 4. The
average M-PAC-SYM, ABD, and M-STO scores were
1.56 ± 0.82, 1.55 ± 0.92, and 1.57 ± 0.94, respectively.
The ABD scale was more discriminative of constipated
patients with abdominal pain, while the M-STO scale was
more discriminative of constipated patients that satisfy the
Rome III criteria for functional constipation, but who did not
report abdominal pain. Among these criteria, reduced bowel
frequency was associatedwith the smallest difference in scale
scores (Table 4). Each additional Rome III symptom ascer-
tained by a gastroenterologist corresponded to an increase in
M-PAC-SYM (b = 0.31; x2 = 0.16), ABD (b = 0.19;
x2 = 0.05), M-STO (b = 0.37; x2 = 0.18) scores.
Concurrent validity
Correlations of SF-12 physical composite score with
M-PAC-SYM total score and subscales ranged from -0.33
(M-STO) to -0.39 (M-PAC-SYM) while correlations of
SF-12 mental composite score ranged from -0.32 (M-
STO) to -0.37 (M-PAC-SYM). Correlations of M-PAC-
SYM and satisfaction with treatment effectiveness, side
effects, and convenience ranged from -0.28
(rTSQM:side–STO), to -0.45 (rTSQM: Effectiveness–PAC-SYM: M).
Responsiveness to clinical change
We tested responsiveness to change in 413 patients who
initiated a new treatment during the 3 months preceding
Fig. 1 Bi-factor model with
two first-order factors. Arrows
represents paths from latent





questionnaire items on latent
factors. Note: the term
e represent an error term
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the interview. We observed a strong association between
the M-PAC-SYM scales and patients’ assessment of clin-
ical change after initiating a new therapy in the 3 months
prior to the interview independent of the treatment regimen
(Table 5). Effect size estimates for difference across single
classes of improvement ranged from d = 0.43 to 0.60
(moderate effect size), while effect sizes of regression
estimates ranged from x2 = 0.15 to 0.25 (large effect
size).
Minimal clinically important difference
We assessed anchor-based MCID in 42 patients assessed
longitudinally. Of them, 8 have been assessed three times.
Overall, the longitudinal dataset included 92 valid obser-
vations. We observed an association between longitudinal
variations in global rating of change scores and variations
in M-PAC-SYM scores (p\ 0.01 for all scales). Anchor-
based MCID were 0.24, 0.38, and 0.16 for M-PAC-SYM,
ABD, and M-STO scores, respectively, corresponding to
d = 0.30, 0.39, 0.20 effect size estimates for differences
across classes of improvement. This difference in the total
score translates into a one-point difference in three (or
bigger changes in a smaller number of symptoms) of the 11
items of the M-PAC-SYM general severity scale.
Discussion
PAC-SYM is a key outcome measure in patients with
chronic constipation. [3–6]. The PAC-SYM is used to assess
both general constipation severity and the severity of spe-
cific aspects of this condition, namely abdominal, rectal, and
stool/defecation symptoms. These sub-scales imply that
each cluster of symptoms independently provides a unique,
non-overlapping, piece of information beyond a general
severity factor. However, the original validation sample of
the PAC-SYM was fairly small, and the proposed factor
structure and scoring algorithm have never been replicated.
Additionally, it should be pointed out that the previous
Table 4 Discrimination of modified PAC-SYM scores across clinically different groups
Clinical characteristicsa D (r)
M-PAC-SYM M-ABD M-STO REC
Rome III
Lumpy/hard stools 0.32 (0.40) 0.16 (0.17) 0.39 (0.42) 0.16 (0.19)
Incomplete evacuation 0.44 (0.63) 0.29 (0.36) 0.52 (0.65) 0.25 (0.27)
Obstruction 0.57 (0.74) 0.29 (0.33) 0.68 (0.78) 0.53 (0.68)
Manual maneuvers 0.26 (0.33) 0.04 (0.04) 0.39 (0.43) 0.38 (0.45)
\3 defecations/week 0.03 (0.04) 0.13 (0.15) 0.13 (0.14) 0.06 (0.07)
Strain 0.29 (0.37) 0.22 (0.25) 0.33 (0.36) 0.16 (0.18)
Abdominal pain 0.26 (0.32) 0.44 (0.48) 0.16 (0.17) 0.19 (0.21)
Pain—improves after bowel movement 0.23 (0.29) 0.46 (0.50) 0.10 (0.11) 0.16 (0.18)
Pain—changes after eating 0.25 (0.31) 0.53 (0.60) 0.09 (0.10) 0.16 (0.18)
Pain—is the most important symptom 0.57 (0.74) 0.82 (0.98) 0.42 (0.47) 0.36 (0.41)
Figures represent differences (D) and effect sizes (r) in scores between patients with and without characteristics
Bold font indicates statistically significant differences at p\ 0.05
a Data collected by a gastroenterologists during a regular outpatient visit
Table 5 Adjusted mean M-PAC-SYM score and effect size across classes of clinical change after initiating a new therapy
Global rating of change
Strongly worsened Worsened Unchanged Improved Strongly improved b (x2)
M-PAC-SYM 2.73 2.24 1.75 1.26 0.77 -0.49 (.25)
M-ABD 2.54 2.14 1.74 1.34 0.94 -0.40 (.15)
M-STO 2.83 2.29 1.75 1.21 0.67 -0.54 (.23)
Results represent estimated means, regression coefficients, and effect sizes for each M-PAC-SYM score (total and sub-scales) by classes of
clinical change after therapy switch. Each general linear model has been adjusted by treatment regimen. Regression coefficient b represent the
change in M-PAC-SYM score associated with an one class increase in global rating of change. Effect size estimates x2 represent the strength of
the association between M-PAC-SYM scores and global rating of change classes
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attempts to link pathophysiological abnormalities to symp-
tom clusters lead to limited results [23, 24].
Our study confirmed that the PAC-SYM questionnaire is
a reliable tool in third-level of care consulters with chronic
non-organic constipation, and we have found evidence
partially supporting construct validity through confirmatory
factor analysis. However, the construct validity and suit-
ability of the rectal subscale as an outcome measure in this
population was questionable. The analysis of inter-item
correlation matrix revealed that items belonging to the rectal
domain might indeed be explained by different phenomena
rather than representing rectal symptoms as a stand-alone
concept. This fact was coupled with the high floor effect of
item 7. Overall, these findings suggest that items grouped in
the PAC-SYM rectal domain may not be relevant for the
majority of patients or may represent different clinical
problems, thus reducing scale responsiveness to change,
discrimination of clinically different groups, and construct
validity; these findings might explain the small effect sizes
on this scale observed in recent RCTs [3].
The results of our study offer an evidence-based and
easy solution to such problem. After deletion of item 7
(rectal bleeding or tearing during or after bowel move-
ment), we were able to replicate the new bi-factor model
with two first-order factors (i.e., the original abdominal and
a new stool domains) in both LIRS waves, thus lending
support to the stability of this structure in the population of
interest. The proposed modified version of the PAC-SYM
provided excellent fit to the data, discriminated across
clinically different subgroups, showed strong concurrent
validity with measures of well-being and treatment satis-
faction and was sensitive to clinical changes.
In contrast with the Rome III definition for functional
constipation, abdominal pain or discomfort was not adop-
ted as a criterion of exclusion from our study, in line with
the recent evidence showing that functional constipation
and IBS-C are not distinct entities [10]. In this regard, the
ABD subscale was more discriminative of patients
reporting abdominal pain, whereas the new M-STO sub-
scale was more discriminative of patients reporting symp-
toms related to defecation. These results suggest that within
the continuum of patients with chronic constipation or with
IBS-C, clinical differences may exist and be revealed by
the modified PAC-SYM subscales but not by the original
REC scale which was less discriminative than either the
ABD and M-STO scales, respectively, for each symptom
cluster (Table 4). In addition, the Rome III criterion of
reduced bowel frequency was poorly associated with the
severity of constipation, in line with previous studies
among patients who self-reported constipation in whom
bowel frequency was normal in about half of the cases [25,
26] and infrequent bowel movements was scored only as
the fifth most bothersome symptom [25].
A further important aim of our study was to establish
anchor-based minimal clinically important differences for
PAC-SYM general factor and its subscales, a key property
allowing the interpretation of scores in research and clinical
practice. The Food and DrugAdministration and EMEA have
recommended that investigators classify responders for the
primary outcome in RCTs based upon a priori rules reflecting
clinically meaningful symptom improvements. We have
shown that anchor-based MCID relative to a global rating of
change scale corresponds to a weak–moderate effect size,
consistent with previous recommendations in this field of
research [16–22]. In previous RCTs, authors defined clinical
response based on a one-point change in PAC-SYM score [3],
which is much greater than the anchor-basedMCID observed
in our study (0.24 in repeatedmeasure analysis), thus possibly
underestimating the response rate [3–6]. Our data provide
evidence-based minimal clinically important differences for
interpreting differences in M-PAC-SYM total score observed
in clinical trials and epidemiologic studies. The MCID found
in our study translates into a one-point difference in 3 (or
bigger changes in a smaller number of symptoms) of the 11
items of the M-PAC-SYM general severity scale.
Our study has several strengths. We were able to com-
prehensively assess the psychometric properties of the
PAC-SYM questionnaire in a large sample of patients with
chronic non-organic constipation and cross-validate our
results in an independent sample of the same population
lending support to the stability of our results.
However, we must also acknowledge some limitations.
Since, we enrolled patients with a long history of consti-
pation from third level of care outpatient clinics, our results
might not generalize to all subjects with constipation. In
particular, we cannot exclude that issues relative to the
rectal scale such as rectal bleeding or tearing during or
after bowel movement might be more pronounced in other
clinical settings, such as primary health care or colo-
proctology units, where patients with acute symptoms are
possibly more common. The invariance of the factor
structure observed in our samples should be tested in
patients with different clinical profiles and health care
seeking behavior. Additionally, our MCID assessment
relied on a small sample of patients who were assessed
longitudinally. As a consequence, we cannot exclude that
selection bias and classification bias have occurred.
In conclusion, our study confirmed that the PAC-SYM
questionnaire is a reliable tool for the assessment of con-
stipation severity and partially supports its construct
validity. However, we showed that the validity of the rectal
symptoms sub-scale is questionable in patients with
chronic constipation, indicating that this scale should not
be used to assess constipation severity in this population. A
global constipation severity score and its subscales defining
abdominal and stool-related symptoms derived from a
1604 Qual Life Res (2015) 24:1597–1605
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modified 11-item version might better represent symptom
severity of most patients seeking care in gastroenterology
referral centers and should be used instead of the original
PAC-SYM version in this population.
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